Perspective Therapeutics

Perspective Therapeutics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Perspective Therapeutics (CATX) as of Oct 31, 2026 is -4.01. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.11 — a change of -2.51% (higher).

EV/FCF

-4.01

YoY

-2.51%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Perspective Therapeutics is 2025 -4.01 . EV/FCF (Enterprise Value to Free Cash Flow) of Perspective Therapeutics was 2024 -4.11 . It decreases by -2.51% higher compared to the previous year.

The Perspective Therapeutics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-86.08 USD
Jan 1, 2019
-94.44 USD
Jan 1, 2020
-133.29 USD
Jan 1, 2021
-143.03 USD
Jan 1, 2022
-58.74 USD
Jan 1, 2023
-38.51 USD
Jan 1, 2024
-4.11 USD
Jan 1, 2025
-4.01 USD
The Perspective Therapeutics EV/FCF history
YEAREV/FCFYoY
-4.01-2.51%
-4.11-89.33%
-38.51-34.44%
-58.74-58.93%
-143.03+7.31%
-133.29+41.14%
-94.44+9.72%
-86.08+4.62%
-82.27-29.64%
-116.94-15.69%
-138.71-10.57%
-155.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Perspective Therapeutics is -4.01 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Perspective Therapeutics changed from -4.11 to -4.01, representing a -2.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Perspective Therapeutics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Perspective Therapeutics